HBO Kennisbank

2 Resultaten

Sorteer op:

Zocht je misschien: ridder, reimer?

Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 Diabetes

van der Hoek, Sjoukje; Willemsen, Antoon T.M.; Visser, Ton; Heeres, Andre (Biobased Chemistry & Refinery); Mulder, Douwe J.; Bokkers, Reinoud P.H.; Slart, Riemer H.J.A.; Elsinga, Philip H.; Heerspink, Hiddo J.L.; Stevens, Jasper

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, including canagliflozin, reduce the risk of cardiovascular and kidney outcomes in patients with and without type 2 diabetes, albeit with a large interindividual variation. The underlying mechanisms for this variation in response might be attributed …

2023-03-10AlgemeenArtikel

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [11C]Telmisartan

van der Hoek, Sjoukje; Mulder, Douwe J.; T.M. Willemsen, Antoon; Visser, Ton J.; Heeres, André (Biobased Chemistry & Refinery); Slart, Riemer H.J.A.; Elsinga, Philip H.; Heerspink, Hiddo J. L.; Stevens, Jasper

The angiotensin receptor blocker telmisartan slows progression of kidney disease in patients with type 2 diabetes (T2D), yet many patients remain at high risk for progressive kidney function loss. The underlying mechanisms for this response variation might be attributed to differences in angiotensin-1 …

2022-09-07AlgemeenArtikel

Vorige Volgende

Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 Diabetes

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [11C]Telmisartan

Over HBO Kennisbank